Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 109, Issue 1, 2007, Pages 23-26

  Zadro, Ivana ^a   Brinar, Vesna ^b   Horvat, Gordana ^b   Brinar, Marko ^c  

^a Croatian Academy of Medical Sciences   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Clinical type; Multiple sclerosis; Myelin oligodendrocyte glycoprotein

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; RECURRENT DISEASE; SAMPLE; STATISTICAL ANALYSIS;

ADULT; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-ASSOCIATED GLYCOPROTEIN; OLIGOCLONAL BANDS; SENSITIVITY AND SPECIFICITY;

EID: 33845232613     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2006.04.006     Document Type: Article

References (23)

1. Lebar R., Lubetzki C., Vincent C., Lombrail P., and Boutry J.M. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 66 (1986) 423-434
2. Amiguet P., Gardinier M., Zanetta J., and Matthieu J. Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein. J Neurochem 58 (1992) 1676-1682
3. Linington C., Bradl M., Lassmann H., Brunner C., and Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130 (1988) 443-454
4. Scolding N., Frith S., Linington C., Morgan B., Campbell A., and Compston D. Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol 22 (1989) 169-176
5. Poser C.M. The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 108 3 (2006 Mar) 227-233
6. Poser C.M. The pathogenesis of multiple sclerosis: a commentary. Clin Neurol Neurosurg 102 4 (2000) 191-194
7. Poser C.M., and Brinar V.V. The nature of multiple sclerosis. Clin Neurol Neurosurg 106 3 (2004) 159-171
8. Kerero de Rosbo N., Honegger P., Lassman H., and Matthieu J. Demyelination induced in aggregating brain cell cultures by monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 55 (1990) 583-587
9. Lassmann H., Brunner C., Brandl M., and Linington C. Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinating lesions. Acta Neuropathol 75 (1988) 566-576
10. Johns T., Kerlero de Rosbo N., Menon K., Abo S., Gonzales M., and Bernard C. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 154 (1995) 536-554
11. Storch M., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M., et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8 (1998) 681-694
12. Genain C., Cannella B., Hauser S., and Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5 (1999) 170-175
13. Raine C., Cannella B., Hauser S., and Genain C. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody meditation. Ann Neurol 46 (1999) 144-160
14. Karni A., Bakimer-Kleiner R., Abramsky O., and Ben-Nur A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 56 (1999) 311-315
15. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., Bonifacio E., et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62 (2004) 2092-2094
16. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., et al. Antibodies against myelin oligodendrocyte glycoprotein and myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122 (1999) 2047-2056
17. Lindert R., Haase C., Brehm U., Linington C., Wekerle H., and Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122 (1999) 2089-2100
18. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349 (2003) 139-145
19. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler 10 Suppl 1 (2004) 2-7
20. Hohlfeld R. Immunologic factors in primary progressive multiple sclerosis. Mult Scler 10 Suppl 1 (2004) 16-22
21. McDonald W., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50 (2001) 121-127
22. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
23. Mantegazza R., Cristaldini P., Bernasconi P., Baggi F., Pedotti R., Piccini I., et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 16 (2004) 559-565